Sign In
Buy VIR
$8.77
+0.0300 (+0.343%)
At Close: Jun 03, 2026
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
06:10pm, Monday, 13'th Jan 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
02:32pm, Friday, 10'th Jan 2025
On Wednesday, Vir Biotechnology, Inc. VIR presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid tumors, and V
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
12:45pm, Thursday, 09'th Jan 2025
Vir Biotechnology posts encouraging initial data from phase I studies evaluating VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors.
Vir Biotechnology: A Rocket Off Phase 1 Data
09:00am, Thursday, 09'th Jan 2025
Vir Biotechnology's recent share price rally is driven by their promising cancer program, despite their primary focus on hepatitis management. The company's market cap has surged past $1 billion, rais
Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why
12:28pm, Wednesday, 08'th Jan 2025
On Wednesday, Vir Biotechnology, Inc. VIR stock traded higher after the company presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety o
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, targeting a variety of HER2
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
09:30am, Wednesday, 18'th Dec 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan He
Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January
12:57pm, Friday, 13'th Dec 2024
VIR's is expected to report data in January from two phase 1 trials of VIR-5500 and VIR-5818, two T-cell engagers, in various cancer types. JANX recently produced promising data with JANX007, which is
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designati
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs
09:30am, Tuesday, 26'th Nov 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will host a virtual investor event to discuss initial data from the dual-masked Phase 1 T-cell engagers VIR-5818
Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference
09:30am, Monday, 25'th Nov 2024
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (NASDAQ:VIR) today announced positive results from the SOLSTICE Phase 2 clinical trial evaluating tobevibart alone, or in combination with elebs
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has issued a positive opi
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart and el
Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off
11:29am, Tuesday, 05'th Nov 2024
VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. However, VIR also pivoted to oncology, discontinuing vaccines and viral immunotherapy, and
